本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 一、 重要提示 证券代码：002589 证券简称：瑞康医药 公告编号：2024-022 瑞康医药集团股份有限公司 2023 年年度股东大会决议的公告 1、本次股东大会未涉及变更以往股东大会已通过的决议。 2、本次股东大会召开期间没有增加、否决或变更议案的情况发生。 二、 会议通知情况 《瑞康医药集团股份有限公司关于召开 2023 年年度股东大会的通知》于 2024 年 4 月 30 日在《证券时报》、《中国证券报》、《证券日报》、《上海证 券报》和巨潮资讯网上已经披露。 三、 会议召开基本情况 1、会议召集人：公司董事会 2、会议时间：2024 年 5 月 21 日（星期二）下午 15:00 3、会议召开地点：山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 4、会议主持人：董事长、总裁韩旭先生 5、会议召开方式：现场会议结合网络投票方式 6、本次会议的召集、召开符合《公司法》、《上市公司股东大会规则》、 《深圳证券交易所股票上市规则》及《公司章程》等有关法律、法规及规范性文 件的规定。 四、 会议出席情况 ...

山东乾元律师事务所·法律意见书 关于瑞康医药集团股份有限公司 2023 年年度股东大会的律师见证法律意见书 致：瑞康医药集团股份有限公司 山东乾元律师事务所（以下简称"本所"）接受贵公司的委托，指派 衣超律师、孔洪恩律师（以下简称"本所律师"）出席贵公司于 2024 年 5 月 21 日下午 15 点在位于山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 举行的 2023 年年度股东大会（以下简称"本次股东大会"），并根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》及《上市公司股东大会规则》等法律法规及规范性文件和《瑞康医药 股份集团有限公司章程》（以下简称"《公司章程》"）的规定，就本次 股东大会的召集与召开程序、出席会议人员的资格和召集人的资格、审议 事项以及表决方式、表决程序、表决结果依法进行见证，并出具法律意见。 为出具本法律意见书，本所律师审查了贵公司提供的以下文件，包括: 1、贵公司的《公司章程》； 2、贵公司于 2024 年 4 月 29 日召开的第五届董事会第七次会议决议； 3、贵公司于 2024 年 4 月 30 日在《证券时报》、《中国证券报》、《证 ...

Financial Performance - The company's operating revenue for 2023 was CNY 8,034,367,997, a decrease of 34.74% compared to CNY 12,311,277,753 in 2022[23]. - The net profit attributable to shareholders of the listed company was CNY 20,317,689.35, a significant increase of 101.11% from a loss of CNY 1,831,651,850 in the previous year[23]. - The net cash flow from operating activities decreased by 84.23% to CNY 82,466,692.06 from CNY 523,073,874.41 in 2022[23]. - Basic earnings per share for 2023 were CNY 0.0135, compared to a loss of CNY 1.2424 in 2022, marking a 101.09% improvement[23]. - Total assets at the end of 2023 were CNY 16,709,306,031, down 8.85% from CNY 18,331,074,646 at the end of 2022[23]. - The net assets attributable to shareholders of the listed company increased by 0.75% to CNY 5,447,793,713.64 from CNY 5,407,787,638.47 in 2022[23]. - The company achieved total revenue of 8.034 billion yuan in 2023, with a net profit attributable to shareholders of 20.3177 million yuan, marking a turnaround from loss to profit[49]. - The total revenue for 2023 was approximately ¥7.1 billion, representing a year-over-year increase of 10.11%[70]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 20%[135]. - The company reported a significant increase in revenue, achieving a total of 10 billion RMB, representing a year-over-year growth of 15%[141]. Market and Business Strategy - The company is actively expanding into the traditional Chinese medicine sector while maintaining its presence in the pharmaceutical distribution industry[37]. - The overall pharmaceutical market in China is expected to reach ¥2.29 trillion by 2025, with a compound annual growth rate of over 7.2%[36]. - The company is focusing on high-margin products and has strategically abandoned low-margin products, resulting in improved cash flow and reduced bad debt ratio[47]. - The company is actively expanding its healthcare ecosystem, including traditional Chinese medicine clinics and pharmacies, while implementing a digital healthcare strategy[61]. - The company is considering strategic acquisitions to enhance its market position, with a budget allocation of 10 million for potential deals[131]. - The company plans to enhance its strategic focus on the traditional Chinese medicine sector, aiming for innovation in product development and commercialization[60]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[135]. Research and Development - The company has invested in R&D for traditional Chinese medicine, with a new drug for lipid reduction expected to enter clinical trials in 2024[48]. - The traditional Chinese medicine segment applied for 12 Chinese patents, with 3 granted, and is developing new products in collaboration with universities, including a new lipid-lowering capsule expected to receive clinical approval in 2024[59]. - The company is investing 2 million in research and development for new technologies aimed at enhancing product efficiency[131]. - Ongoing research and development efforts are focused on enhancing product efficacy, with an investment of 200 million RMB allocated for new technologies[144]. Operational Efficiency - The company has implemented a digital transformation strategy, enhancing operational efficiency and reducing management costs through better procurement and inventory management[48]. - The logistics capabilities have been enhanced with a modern smart pharmaceutical supply chain, improving safety and efficiency in distribution[63]. - The company aims to improve operational efficiency by 20% through new strategies implemented in 2024[131]. - The management team emphasized the importance of operational efficiency, aiming to reduce costs by 8% through process optimization[144]. Governance and Compliance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations, and promoting effective decision-making and oversight[112]. - The board of directors consists of nine members, including three independent directors, ensuring a diverse and professional governance framework[114]. - The company maintains independence from its controlling shareholders, with no instances of fund or asset misappropriation reported during the reporting period[119]. - The company has implemented a comprehensive internal audit system to oversee financial operations and mitigate risks associated with internal controls[118]. - The company is committed to transparent information disclosure and investor relations, ensuring timely and accurate communication with stakeholders[117]. Employee and Talent Management - The company has established a comprehensive salary and benefits system, along with a performance evaluation system to attract and retain talent[157]. - The total number of employees at the end of the reporting period was 3,239, with 1,828 from major subsidiaries and 220 from the parent company[156]. - The company has a training system in place that includes various aspects such as corporate culture, leadership, and quality management[158]. - The company has a total of 46 employees with a master's degree or above, and 907 employees with a bachelor's degree[156]. - The employee stock ownership plan (ESOP) involved 97 employees holding a total of 30,398,300 shares, representing 2.02% of the company's total equity[165]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, implementing energy-saving measures across all departments[186]. - The company encourages employees to participate in social welfare activities, supporting various charitable causes[187]. - The company has established a system for energy-saving targets and promotes a culture of resource conservation among employees[186]. - The company has implemented a paperless office initiative to improve paper utilization and reduce waste[186]. Divestitures and Subsidiaries - The company has successfully completed the divestment of subsidiaries, including Shanghai Youronglin Cheng Pharmaceutical Investment Co., Ltd. for ¥80.5 million[196]. - The company completed divestitures of several subsidiaries, including a 51% stake in Beijing Times Rui Ao Trading Co., Ltd. for approximately ¥90,983,076.41 and a 100% stake in Tibet Jinyue Jirui Biotechnology Co., Ltd. for ¥32,000,000.00[197]. - The company has divested from multiple subsidiaries, with total divestiture amounts exceeding ¥200 million across various agreements, indicating a significant restructuring effort[197]. - The company has established new subsidiaries, including Qingdao Hexi Hui Technology Investment Co., Ltd. with a registered capital of ¥5,000,000 and Yantai Ruikang Yishou Shared Economic Service Co., Ltd. with a registered capital of ¥1,030,000[198].

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日在巨 潮资讯网（www.cninfo.com.cn）上披露了 2023 年年度报告全文及其摘要。为进 一步加强公司与投资者的沟通交流，建立良好沟通机制，让广大投资者能深入了 解公司经营情况、未来发展战略等，公司拟举办 2023 年年度业绩说明会（以下 简称"业绩说明会"）。 具体安排如下： 一、业绩说明会召开的时间和方式 召开时间：2024 年 5 月 8 日（星期三）下午 15:00-17:00。 召开方式：本次业绩说明会将采用网络文字互动的方式召开。 证券代码：002589 证券简称：瑞康医药 公告编号：2024-014 瑞康医药集团股份有限公司 关于举办 2023 年度网上业绩说明会的公告 三、投资者问题征集 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。公司欢迎广大投资者于 2024 年 5 月 7 日（星期二）17:30 前访问 http://irm.cninfo.c ...

Financial Performance - The company's revenue for Q1 2024 was ¥2,018,758,765.18, a decrease of 2.62% compared to ¥2,073,027,669.16 in the same period last year[5] - Net profit attributable to shareholders decreased by 28.31% to ¥15,168,972.69 from ¥21,159,565.23 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased significantly by 526.70% to ¥18,162,174.56, compared to a loss of ¥4,256,424.09 in the previous year[5] - Net profit for Q1 2024 was CNY 18,571,098.80, a decline of 38.2% compared to CNY 29,983,448.04 in Q1 2023[24] - The net profit attributable to shareholders of the parent company was CNY 15,168,972.69, down 28.4% from CNY 21,159,565.23 in the previous year[24] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.010, compared to CNY 0.014 in Q1 2023[24] Cash Flow - The net cash flow from operating activities was negative at -¥54,084,542.82, a decline of 171.55% from ¥75,590,663.40 in the same period last year[5] - Cash received from operating activities decreased by 55.70% to ¥8,108.61 from ¥18,304.63 in the same period last year[13] - The net cash flow from operating activities for Q1 2024 was -54,084,542.82, compared to a positive net cash flow of 75,590,663.40 in Q1 2023, indicating a significant decline[27] - Cash paid for operating activities totaled 2,231,248,746.34, compared to 2,352,780,522.41 in the previous year, indicating a decrease of approximately 5%[27] - The cash received from the disposal of subsidiaries and other business units was 81,419,056.38, down from 334,580,526.88 in Q1 2023, marking a decline of about 76%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥15,558,939,780.85, down 6.88% from ¥16,709,306,031.48 at the end of the previous year[5] - The company’s total liabilities increased, with notes payable rising by 235.93% to ¥150,696.14 from ¥44,859.88 year-on-year[10] - Total liabilities decreased to CNY 9,903,391,687.96 from CNY 11,072,329,037.39 year-over-year[23] - The total number of common shareholders at the end of the reporting period is 83,325[15] - The largest shareholder, Zhang Renhua, holds 13.39% of shares, totaling 201,498,159 shares, with 90,874,100 shares pledged[15] Investment and Expenses - Investment income dropped by 90.61% to ¥500.35 from ¥5,328.83 year-on-year due to the divestiture of subsidiaries[11] - The company reported a 53.21% decrease in financial expenses to ¥5,565.88 from ¥11,894.68 in the previous year[11] - Research and development expenses for Q1 2024 were CNY 3,103,612.68, an increase from CNY 2,846,655.14 in the same period last year[23] - The company reported a financial expense of CNY 55,658,801.00, significantly reduced from CNY 118,946,779.26 in Q1 2023[23] Inventory and Receivables - Accounts receivable increased from 3,762,988,324.45 RMB to 3,950,732,855.74 RMB, reflecting a growth of approximately 5%[19] - Inventory decreased from 1,119,070,006.89 RMB to 978,041,450.83 RMB, a decline of about 12.6%[19] Cash and Equivalents - The company's cash and cash equivalents decreased from 5,060,786,524.48 RMB to 4,022,756,394.67 RMB[18] - The total cash inflow from financing activities was 5,942,289,521.45, while cash outflow was 5,831,685,791.87, resulting in a net inflow of 110,603,729.58[27] - The total cash and cash equivalents increased by 130,806,158.63 during the quarter, compared to an increase of 381,285,003.94 in Q1 2023[27]

证券代码：002589 证券简称：瑞康医药 公告编号：2024-011 瑞康医药集团股份有限公司 关于实际控制人股份质押和解除质押的公告 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人韩旭先 生的函告，获悉其收到中国证券登记结算有限责任公司股份质押登记证明，获悉 韩旭先生所持有本公司的部分股份已质押，部分股份已解除质押，具体事项如下： | 股东名 | 是否为控 股股东或 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起始 | 质押到期 | | 质押用 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 第一大股 | 数量 | 持股份 | 总股本 | 限售股 | 补充质 | 日 | 日 | 质权人 | 途 | | | 东及其一 | （万股） | 比例 | 比例 | | 押 | | | | | | | 致行动人 | | | | | | | | | | | 韩旭 | | | | | | | 2024 年 3 | 2025 年 4 | 国民信 | 补充流 | | | 是 | 50 ...

关于全资子公司为上市公司提供担保的公告 证券代码：002589 证券简称：瑞康医药 公告编号：2024-010 瑞康医药集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、担保情况概述 瑞康医药集团股份有限公司（以下简称"公司"）于 2022 年 10 月 28 日召开 第四届董事会第二十三次会议，审议通过了《关于公司及全资、控股子公司向 境内外相关金融机构申请综合授信额度调整的议案》，同意公司及全资、控股 子公司向境内外相关银行申请总额不超过 100 亿元人民币的综合授信额度（其 中母公司实际使用综合授信敞口不超过人民币 70 亿元，子公司实际使用综合授 信敞口不超过人民币 30 亿元），融资期限不超过 5 年（含 5 年），授信业务包 括但不限于贷款、承兑汇票、信用证、保理等，银行综合授信业务的担保方式 为信用、保证、抵押、质押等。本次申请授信事项自董事会审议通过之日起两 年内有效。具体内容详见公司于 2022 年 10 月 31 日在《中国证券报》《证券时 报》《证券日报》《上海证券报》及巨潮资讯网（http://www.cninfo. ...

证券代码：002589 证券简称：瑞康医药 公告编号：2024-009 瑞康医药集团股份有限公司 关于实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人韩旭先 生的函告，获悉其收到中国证券登记结算有限责任公司股份质押登记证明，所持 有本公司的部分股份已完成质押，具体事项如下： 三、股东股份是否存在平仓风险或被强制过户风险 公司实际控制人韩旭先生和张仁华女士资信状况良好，具备相应的资金偿还 能力，目前不存在平仓风险，也不会导致其实际控制权发生变更。 公司控股股东未来股份变动如达到《证券法》、《上市公司收购管理办法》 等规定的相关情形的，将严格遵守权益披露的相关规定，及时履行信息披露义务。 三、控股股东及其一致行动人股份质押情况 （1）本次股份质押融资不涉及满足上市公司生产经营的相关需求。 （2）韩旭先生、张仁华女士未来半年到期的质押股票累计数量为 5,520 万 股，对应融资余额为 7,000 万元,占其所持股份比例 14.26%，占公司总股本比例 3.67%；未来一年到期 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2024-005 瑞康医药集团股份有限公司 关于调整第五届董事会审计委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述和重大遗漏。 1 董 事 会 2024 年 2 月 6 日 特此公告。 根据中国证券监督管理委员会发布的《上市公司独立董事管理办法》规定， 审计委员会成员应当为不在上市公司担任高级管理人员的董事，因李喆先生为瑞 康医药集团股份有限公司（以下简称"公司"）高级管理人员，不符合担任第五届 董事会审计委员会委员的要求。为进一步完善公司治理结构，保障公司董事会专 门委员会规范运作，更好地发挥公司董事会各专业委员会作用。 公司于 2024 年 2 月 5 日召开第五届董事会第六次会议，审议通过了《关于 调整公司第五届董事会审计委员会委员的议案》，公司董事会同意选举吴丽艳女 士担任公司第五届董事会审计委员会委员，任期自董事会审议通过之日起至第五 届董事会届满之日止。本次调整后，公司第五届董事会审计委员会成员为：柳喜 军（独立董事）、王吉法（独立董事）、吴丽艳（董事），其中独立董事柳喜军 先生为召集人。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2024-008 特此公告。 瑞康医药集团股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）第五届监事会第六次会议 通知于 2024 年 1 月 31 日以书面形式发出，2024 年 2 月 5 日下午在烟台市芝罘 区凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会议由张岩女士 主持，会议应出席监事 3 名，实际出席监事 3 名。会议的召开符合《中华人民共 和国公司法》和《公司章程》的规定。经与会监事审议，会议形成如下决议： 一、审议通过《关于公司新增对外担保的议案》 经审核，为帮助北京诺亚阳光科技发展有限公司（以下简称"诺亚阳光"）、 北京旭日鸿升生物技术有限公司（以下简称"旭日鸿升"）拓宽融资渠道，及时 获得经营发展所需要的资金，加快资金周转和回收，同意向诺亚阳光、旭日鸿升 提供连带责任担保，合计金额为 1,500 万元，保证期间为主合同项下相应债务到 期日起一年，实际担保金额和担保范围以签订的担保合同为准。我们认为：公司 申请新 ...